| DC Field | Value | Language |
|---|
| dc.contributor.author | Naletova, E.N. | - |
| dc.contributor.author | Naletova, O.S. | - |
| dc.contributor.author | Serdyuk, E.B. | - |
| dc.contributor.author | Naletov, S.V. | - |
| dc.contributor.author | Alesinsky, M.M. | - |
| dc.date.accessioned | 2025-08-19T08:53:45Z | - |
| dc.date.available | 2025-08-19T08:53:45Z | - |
| dc.date.issued | 2025 | - |
| dc.identifier.citation | Pharmacoepidemiologic and clinical rationale for the inclusion of L-arginine and dihydroquercetin in the combined pharmacotherapy of hypertensive patients with COVID-19 / E.N. Naletova, O.S. Naletova, E.B. Serdyuk [et al.] // Research Results in Pharmacology. - 2025. - Vol.11, №1.-P. 36-48. - Doi: 10.18413/rrpharmacology.11.469. - Refer.: p. 47-48. | ru |
| dc.identifier.uri | http://dspace.bsuedu.ru/handle/123456789/65285 | - |
| dc.description.abstract | The aim was to improve the effectiveness of treatment of COVID-19-treated HD patients by pharmacoepidemiologic and clinical substantiation of inclusion of L-arginine + dihydroquercetin complex in the composition of combined AHPT | ru |
| dc.language.iso | en_US | ru |
| dc.subject | medicine | ru |
| dc.subject | pharmacology | ru |
| dc.subject | arterial hypertensio | ru |
| dc.subject | COVID-19 | ru |
| dc.subject | combined antihypertensive pharmacotherapy | ru |
| dc.subject | L-arginine | ru |
| dc.subject | dihydroquercetin | ru |
| dc.title | Pharmacoepidemiologic and clinical rationale for the inclusion of L-arginine and dihydroquercetin in the combined pharmacotherapy of hypertensive patients with COVID-19 | ru |
| dc.type | Article | ru |
| Appears in Collections: | Vol. 11, № 1
|
